Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.

Muromonab Biosimilar(Anti-CD3 Reference Antibody)

  Cat. No.:  A1060   Featured
Chemical Structure
140608-64-6
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection.
Cas No.: 140608-64-6
pH value: Corresponds to reference standard: PASS
Non-reduced CE-SDS: >95%
SEC-HPLC: >95%
Isoelectric Point: Corresponds to reference standard
Osmolality: Corresponds to reference standard: PASS
Peptide mapping: Corresponds to reference standard: PASS
N-terminal sequence: Corresponds to reference standard: PASS
MSDS
Cat. No. Product name Field of application
A1061 Osemitamab Biosimilar(Anti-CLDN18.2 Reference Antibody) Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study.
A1060 Muromonab Biosimilar(Anti-CD3 Reference Antibody) Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection.
A1059 Atoltivimab Biosimilar(Anti-EBOV Reference Antibody) Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection.
A1058 Navivumab Biosimilar(Anti-HA Reference Antibody) Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2.
A1057 Anti-IAV Reference Antibody Biosimilar
A1056 Odesivimab Biosimilar(Anti-Zaire Ebola virus Reference Antibody) Odesivimab is a human monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection.
A1055 Cosfroviximab Biosimilar(Anti-Zaire Ebola virus Reference Antibody) Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP).
A1054 Porgaviximab Biosimilar(Anti-Zaire Ebola virus Reference Antibody) Porgaviximab is a monoclonal antibody that can be used Ebola infection research.
A1053 Larcaviximab Biosimilar(Anti-Zaire Ebola virus Reference Antibody) Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody.
A1052 Romlusevimab Biosimilar(Anti-Spike RBD Reference Antibody) Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
X